SG48737A1 - Substituted-1,3-oxathiolanes with antiviral properties - Google Patents

Substituted-1,3-oxathiolanes with antiviral properties

Info

Publication number
SG48737A1
SG48737A1 SG1996001044A SG1996001044A SG48737A1 SG 48737 A1 SG48737 A1 SG 48737A1 SG 1996001044 A SG1996001044 A SG 1996001044A SG 1996001044 A SG1996001044 A SG 1996001044A SG 48737 A1 SG48737 A1 SG 48737A1
Authority
SG
Singapore
Prior art keywords
oxathiolanes
substituted
antiviral properties
antiviral
properties
Prior art date
Application number
SG1996001044A
Other languages
English (en)
Inventor
Bernard Belleau
Nguyen-Ba Nghe
Original Assignee
Iaf Biochem Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25678044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG48737(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int
Priority claimed from CA002152269A external-priority patent/CA2152269C/en
Publication of SG48737A1 publication Critical patent/SG48737A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/40Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
SG1996001044A 1989-02-08 1990-02-08 Substituted-1,3-oxathiolanes with antiviral properties SG48737A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/308,101 US5047407A (en) 1989-02-08 1989-02-08 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
CA002152269A CA2152269C (en) 1989-02-08 1992-12-21 Process for preparing substituted 1,3-oxathiolanes with antiviral properties

Publications (1)

Publication Number Publication Date
SG48737A1 true SG48737A1 (en) 1998-05-18

Family

ID=25678044

Family Applications (2)

Application Number Title Priority Date Filing Date
SG1996001044A SG48737A1 (en) 1989-02-08 1990-02-08 Substituted-1,3-oxathiolanes with antiviral properties
SG1999000115A SG77215A1 (en) 1989-02-08 1990-02-08 Substituted-1,3-oxathiolanes with antiviral properties

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG1999000115A SG77215A1 (en) 1989-02-08 1990-02-08 Substituted-1,3-oxathiolanes with antiviral properties

Country Status (35)

Country Link
US (1) US5047407A (de)
EP (2) EP0711771B1 (de)
JP (4) JP2644357B2 (de)
KR (1) KR960007531B1 (de)
CN (1) CN1033640C (de)
AP (1) AP136A (de)
AT (2) ATE138065T1 (de)
AU (1) AU630913B2 (de)
CA (1) CA2009637C (de)
CY (1) CY2036A (de)
CZ (1) CZ282720B6 (de)
DE (3) DE69034119T2 (de)
DK (2) DK0382526T3 (de)
ES (2) ES2206476T3 (de)
FI (1) FI98065C (de)
GR (1) GR3019919T3 (de)
HK (2) HK51997A (de)
HR (1) HRP940040B1 (de)
HU (2) HU208134B (de)
IE (1) IE72184B1 (de)
IL (1) IL93318A (de)
LU (1) LU88809I2 (de)
MX (1) MX19437A (de)
NL (1) NL960025I2 (de)
NO (2) NO179518C (de)
NZ (1) NZ232421A (de)
OA (1) OA09193A (de)
PL (1) PL164785B1 (de)
PT (1) PT93094B (de)
RU (1) RU2092485C1 (de)
SG (2) SG48737A1 (de)
SI (1) SI9010243B (de)
SK (1) SK279175B6 (de)
YU (1) YU48840B (de)
ZA (1) ZA90943B (de)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5684164A (en) * 1988-04-11 1997-11-04 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US6903224B2 (en) * 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
HU226137B1 (en) * 1989-02-08 2008-05-28 Shire Canada Inc Process for preparing substituted 1,3-oxathiolanes with antiviral properties
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5827727A (en) * 1990-02-01 1998-10-27 Emory University Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
WO1992008717A1 (en) * 1990-11-13 1992-05-29 Biochem Pharma Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US6369066B1 (en) 1990-11-13 2002-04-09 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes with antiviral properties
US6228860B1 (en) 1990-11-13 2001-05-08 Biochem Pharma Inc. Substituted 1,3-oxathiolanes with antiviral properties
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2 - Hydroxymethyl - 5 -) 5 - Fluorocytocin - 1 - Eyal (- 1, 3 - Oxathiolane, its resolution and pharmaceuticals containing it
US6812233B1 (en) * 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
IL101144A (en) * 1991-03-06 1996-09-12 Wellcome Found Pharmaceutical preparations containing 1 -) 2 -) hydroxymethyl (- 1, 3 - oxathiolan-5 - il (5) fluorescitosin and its derivatives for the treatment of their hepatitis B virus infections
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
WO1992020344A1 (en) * 1991-05-16 1992-11-26 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
ATE138928T1 (de) * 1991-09-04 1996-06-15 Stichting Rega V Z W Substituierte nukleosidderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
ES2138624T3 (es) * 1992-05-13 2000-01-16 Wellcome Found Combinaciones terapeuticas.
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US6005107A (en) * 1992-12-23 1999-12-21 Biochem Pharma, Inc. Antiviral compounds
US6444656B1 (en) 1992-12-23 2002-09-03 Biochem Pharma, Inc. Antiviral phosphonate nucleotides
GB9226879D0 (en) * 1992-12-23 1993-02-17 Iaf Biochem Int Anti-viral compounds
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
WO1995007086A1 (en) * 1993-09-10 1995-03-16 Emory University Nucleosides with anti-hepatitis b virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) * 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
FR2720397B1 (fr) * 1994-05-24 1996-08-23 Laphal Laboratoires Sa Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
WO1996031217A1 (en) * 1995-04-04 1996-10-10 Duke University Inhibiting retroviral replication
DE69636734T2 (de) 1995-06-07 2007-10-18 Emory University Nucleoside mit anti-hepatitis b virus wirksamkeit
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments
FR2746396B1 (fr) * 1996-03-20 1998-06-05 Inst Nat Sante Rech Med 1,3-thiazolidin-4-ones et 1,3-thiazolidines substituees, procede d'obtention de ces composes et leurs utilisations comme medicaments
NZ333099A (en) 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US20040044016A1 (en) * 1997-01-31 2004-03-04 Mitsubishi Chemical Corporation Antiviral agents
ATE267198T1 (de) * 1997-03-19 2004-06-15 Univ Emory Synthese und anti-hiv und anti-hepatitis virus aktivität von 1,3-oxaselenolan nucleosiden
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
IT1290447B1 (it) 1997-03-28 1998-12-03 Zambon Spa Derivati 1,3-ossatiolanici ad attivita' antivirale
US6410546B1 (en) 1997-04-07 2002-06-25 Triangle Pharmaceuticals, Inc. Use of MKC-442 in combination with other antiviral agents
EA200700564A1 (ru) 1998-02-25 2007-08-31 Эмори Юниверсити 2`-фторнуклеозиды
EP1754710A3 (de) 1998-02-25 2007-12-19 Emory University 2'-Fluoronukleoside
JP4249393B2 (ja) 1998-08-12 2009-04-02 トライアングル・ファーマシューティカルズ,インコーポレイテッド 1,3−オキサチオランヌクレオチドの製造方法
US6979561B1 (en) 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
CN1666742A (zh) 1998-11-02 2005-09-14 三角药物公司 对乙型肝炎病毒的联合治疗
KR100618028B1 (ko) 1998-11-05 2006-08-30 쌍트르 나쉬오날 드 라 르쉐르스 쉬앙티피끄 항-b형 간염 활성을 가진 뉴클레오시드
CA2355712C (en) 1998-12-23 2009-03-17 Shire Biochem Inc. Antiviral nucleoside analogues
SK13822001A3 (sk) * 1999-03-29 2002-02-05 Shire Biochem Inc. Použitie zlúčenín podľa vynálezu na prípravu farmaceutických prostriedkov na liečenie leukémie
US6752929B1 (en) * 1999-05-26 2004-06-22 Johnson Matthey Pharmaceutical Materials, Inc. Methods of separating FTC isomers and derivatives thereof
US6541631B1 (en) 1999-05-26 2003-04-01 Pharma-Eco Laboratories, Inc. Methods of separating FTC isomers and derivatives thereof
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
WO2001034618A2 (en) * 1999-11-12 2001-05-17 Pharmasset Limited Synthesis of 2'-deoxy-l-nucleosides
EP1600452A3 (de) 1999-11-12 2008-09-10 Pharmasset, Inc. Herstellung von 2'-Deoxy-L-Nukleoside
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
GB0016845D0 (en) * 2000-07-07 2000-08-30 Leuven K U Res & Dev Pharmaceutical composition for treatment of HIV infection
WO2002051852A1 (fr) * 2000-12-27 2002-07-04 Mitsui Chemicals, Inc. Procede de production d'un derive de saccharide non naturel
CN102911166B (zh) * 2001-03-01 2016-08-17 基利得科学公司 顺-ftc的多晶型物及其它晶型
CA2351049C (en) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
JP2003039582A (ja) * 2001-07-19 2003-02-13 Three M Innovative Properties Co 湿潤防滑性シート及び湿潤防滑構造体
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US6855346B2 (en) * 2001-10-05 2005-02-15 Tzu-Sheng Wu Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
GEP20063848B (en) * 2001-10-26 2006-06-12 Inst Di Richerche Di Biolog Moltcolare P Angeletti Spa N-substituted hydroxypyrimi-dinone carboxamide inhibitors of hiv integrase
BR0214940A (pt) * 2001-12-14 2006-05-30 Pharmasset Ltd preparação de intermediários úteis na sìntese de nucleosìdeos antivirais
EP2266590A3 (de) 2002-02-22 2011-04-20 Shire LLC Wirkstoff-Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Wirkstoffen
ATE496054T1 (de) 2002-08-06 2011-02-15 Pharmasset Inc Verfahren zur herstellung von 1,3-dioxolan- nucleosiden
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
ES2286471T3 (es) * 2002-11-08 2007-12-01 Glaxo Group Limited Composiciones farmaceuticas antivirales.
CN100406017C (zh) * 2002-12-09 2008-07-30 佐治亚大学研究基金会 用于对抗hiv抗性株的二氧戊环基胸腺嘧啶及其组合物
ES2308136T3 (es) * 2003-01-14 2008-12-01 Gilead Sciences, Inc. Composiciones y procedimientos para la politerapia antiviral.
US8044060B2 (en) 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
PT1778251E (pt) 2004-07-27 2011-06-29 Gilead Sciences Inc Análogos de fosfonato de compostos inibidores de vih
JP2006214695A (ja) * 2005-02-07 2006-08-17 Sanken Setsubi Kogyo Co Ltd 空調システム
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
WO2007013047A2 (en) * 2005-07-29 2007-02-01 Ranbaxy Laboratories Limited Water-dispersible anti-retroviral pharmaceutical compositions
CN1328240C (zh) * 2005-08-31 2007-07-25 四川大学 苯甲酰氧基乙醛的制备方法
ATE484284T1 (de) * 2005-08-31 2010-10-15 Cipla Ltd Pharmazeutische kombinationen mit lamivudin, stavudin und nevirapin
EP1937825B1 (de) * 2005-09-26 2016-12-21 Gilead Pharmasset LLC Modifizierte 4'-nukleoside als antivirusmittel
BRPI0620705A2 (pt) * 2005-12-14 2011-11-22 Cipla Ltd formulação farmacêutica em uma forma única de dosagem unitária, produto farmacêutico, uso de uma formulação farmacêutico e uso de um inibidor de transcriptase-reversa de nucleosìdeo ou derivado fisiologicamente funcional do mesmo e um inibidor de transcriptase-reversa de nucleotìdeo ou derivado fisiologicamente funcional do mesmo
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
ES2357159T3 (es) * 2006-04-18 2011-04-19 Lupin Ltd. Forma cristalina novedosa de lamivudina.
EP2086955A2 (de) * 2006-10-30 2009-08-12 Lupin Ltd. Verbessertes verfahren zur herstellung von cis-(-)-lamivudin
KR100840495B1 (ko) 2007-04-13 2008-06-23 한미약품 주식회사 라미부딘을 입체선택적으로 제조하는 방법
EP2159224B1 (de) 2007-06-18 2012-08-01 Sunshine Lake Pharma Co., Ltd Bromphenylsubstituierte thiazolyldihydropyrimidine
US20100190982A1 (en) * 2007-09-17 2010-07-29 Janardhana Rao Vascuri Process for the preparation of lamivudine form i
BRPI0820224A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Composto de fórmula iii ou seus estereoisômeros; processo para sua preparação e seu uso; uso de um composto de formula iii(a) ou iii(b) em um processo para a preparação de lamivudina de fórmula i(a) ou um composto de fórmula i(c); processo para preparação de lamivudina de fórmula i(a)
BRPI0820226A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Processo para o preparo de um 1,3-oxatiolana, para o preparo de lamivudina e para isolar lamivudina, lamivudina e composição farmacêutica
PE20091211A1 (es) * 2007-11-30 2009-09-14 Boehringer Ingelheim Int Derivados de pirazolopirimidina como moduladores de pde9a
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
TW201010692A (en) 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
PE20110383A1 (es) 2008-09-08 2011-07-15 Boehringer Ingelheim Int Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
TWI432436B (zh) 2008-12-09 2014-04-01 Gilead Sciences Inc 類鐸受體的調節劑
US20110282046A1 (en) * 2009-01-19 2011-11-17 Rama Shankar Process for preparation of cis-nucleoside derivative
CA2757231A1 (en) * 2009-03-31 2010-10-07 Boehringer Ingelheim International Gmbh 1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
KR101474570B1 (ko) 2009-04-13 2014-12-19 주식회사 대희화학 라미부딘의 신규한 중간체 및 이의 제조방법
TW201118099A (en) * 2009-08-12 2011-06-01 Boehringer Ingelheim Int New compounds for the treatment of CNS disorders
ES2540074T3 (es) 2009-10-14 2015-07-08 Mylan Laboratories Limited Proceso para la preparación de lamivudina y nuevas sales en la fabricación de la misma
US20120295898A1 (en) 2010-01-27 2012-11-22 Mark Richard Underwood Antiviral Therapy
US20120295930A1 (en) 2010-02-03 2012-11-22 Shankar Rama Novel process for the preparation of cis-nucleoside derivative
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
CN102234269B (zh) * 2010-04-29 2015-09-16 重庆医药工业研究院有限责任公司 拉米夫定的工业化制备方法
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
CN114010776A (zh) 2010-06-09 2022-02-08 疫苗技术股份有限公司 用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
PL2603511T3 (pl) 2010-08-12 2017-08-31 Boehringer Ingelheim Int Pochodne 6-cykloalkilo-1,5-dihydropirazolo[3,4-d]pirymidyn-4-onu i ich zastosowanie jako inhibitorów PDE9A
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2739620A1 (de) 2011-08-05 2014-06-11 Lupin Limited Stereoselektives verfahren zur herstellung von 1,3-oxathiolan-nukleosiden
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN103694231A (zh) * 2013-11-28 2014-04-02 安徽一帆香料有限公司 一种拉米夫定中间体hdms的合成制备方法
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
EP3166607B1 (de) 2014-07-11 2022-08-31 Gilead Sciences, Inc. Modulatoren von toll-like-rezeptoren zur behandlung von hiv
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
EP3349757A1 (de) 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulatoren von toll-like-rezeptoren zur behandlung von hiv
HRP20211687T1 (hr) 2015-12-02 2022-03-04 Merck Sharp & Dohme Corp. Farmaceutske kompozicije koje sadrže doravirin, tenofovir dizoproksil fumarat i lamivudin
WO2018178722A1 (en) * 2017-03-31 2018-10-04 The University Of Liverpool Prodrug compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5259171A (en) * 1975-11-10 1977-05-16 Asahi Chem Ind Co Ltd Preparation of uracil derivatives
JPS6045196B2 (ja) * 1976-08-09 1985-10-08 株式会社興人 1−(2−テトラヒドロフリル)ウラシル類の製造方法
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
JPS56167685A (en) * 1980-05-28 1981-12-23 Taiho Yakuhin Kogyo Kk 1- 2-tetrahydrothiophene-1,1-dioxide -5-fluorouracil and its preparation
JPS56169689A (en) * 1980-06-02 1981-12-26 Taiho Yakuhin Kogyo Kk 3-substituted-5-fluorouracil derivative and its preparation
JPS5738774A (en) * 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
SU1035023A1 (ru) * 1982-03-23 1983-08-15 Ордена Трудового Красного Знамени Институт Органической И Физической Химии Им.А.Е.Арбузова Способ получени 3-(тииранил-2-метил)-6-метилурацилов
DE3324769A1 (de) * 1983-07-08 1985-01-17 Bayer Ag, 5090 Leverkusen 5-aminomethyl-1,3-oxathiolane
EP0206497B1 (de) * 1985-05-15 1994-07-20 The Wellcome Foundation Limited Therapeutische Nucleoside und deren Herstellung
CA1294960C (en) * 1986-10-24 1992-01-28 Thomas C. Malone 7-deazaguanines as immunomodulators
DE3712735A1 (de) * 1987-04-15 1988-11-10 Boehringer Mannheim Gmbh Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
ES2075040T3 (es) * 1988-02-16 1995-10-01 Lilly Co Eli 2',3'-dideoxi-2',2'-difluoronucleosidos.
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds

Also Published As

Publication number Publication date
CN1033640C (zh) 1996-12-25
YU24390A (en) 1991-10-31
JP2000143662A (ja) 2000-05-26
CS410991A3 (en) 1992-07-15
JPH08119967A (ja) 1996-05-14
RU2092485C1 (ru) 1997-10-10
ATE138065T1 (de) 1996-06-15
DE69034119D1 (de) 2003-12-18
AU4920190A (en) 1990-08-16
US5047407A (en) 1991-09-10
NO900619D0 (no) 1990-02-08
EP0711771A2 (de) 1996-05-15
CZ282720B6 (cs) 1997-09-17
DE69034119T2 (de) 2004-08-26
SG77215A1 (en) 2000-12-19
HU900708D0 (en) 1990-04-28
PL164785B1 (en) 1994-10-31
HU210537A9 (en) 1995-04-28
CN1044817A (zh) 1990-08-22
NO2001002I1 (no) 2001-02-12
NZ232421A (en) 1993-10-26
PT93094B (pt) 1995-12-29
SI9010243B (sl) 1998-08-31
EP0382526A2 (de) 1990-08-16
NO179518B (no) 1996-07-15
NL960025I2 (nl) 1997-03-03
KR960007531B1 (ko) 1996-06-05
EP0711771B1 (de) 2003-11-12
ES2086371T3 (es) 1996-07-01
FI900631A0 (fi) 1990-02-08
JP2001226373A (ja) 2001-08-21
IE960758L (en) 1990-08-08
YU48840B (sh) 2002-06-19
HU208134B (en) 1993-08-30
DE69026971D1 (de) 1996-06-20
AP136A (en) 1991-08-05
IE900452L (en) 1990-08-08
OA09193A (en) 1992-06-30
CA2009637C (en) 1997-10-07
PT93094A (pt) 1990-08-31
HUT53362A (en) 1990-10-28
FI98065C (fi) 1997-04-10
EP0382526A3 (de) 1992-01-02
HRP940040A2 (en) 1997-04-30
GR3019919T3 (en) 1996-08-31
IL93318A (en) 1995-07-31
HRP940040B1 (en) 2002-04-30
EP0382526B1 (de) 1996-05-15
KR900012932A (ko) 1990-09-03
ZA90943B (en) 1990-10-31
NO179518C (no) 2000-09-11
JP3105154B2 (ja) 2000-10-30
AP9000163A0 (en) 1990-04-30
SI9010243A (en) 1996-10-31
NO900619L (no) 1990-08-09
NL960025I1 (nl) 1997-01-06
SK279175B6 (sk) 1998-07-08
ES2206476T3 (es) 2004-05-16
JP2644357B2 (ja) 1997-08-25
DE69026971T2 (de) 1996-09-12
DK0382526T3 (da) 1996-08-05
FI98065B (fi) 1996-12-31
HK1009270A1 (en) 1999-05-28
IE72184B1 (en) 1997-03-26
CY2036A (en) 1998-02-20
CA2009637A1 (en) 1990-08-08
LU88809I2 (fr) 1997-01-03
DE19675032I2 (de) 2007-11-08
DK0711771T3 (da) 2004-03-22
JPH037282A (ja) 1991-01-14
EP0711771A3 (de) 1996-07-10
AU630913B2 (en) 1992-11-12
HK51997A (en) 1997-05-02
ATE254125T1 (de) 2003-11-15
MX19437A (es) 1993-05-01

Similar Documents

Publication Publication Date Title
HRP940040B1 (en) Substituted-1,3-oxathiolanes with antiviral properties
EP0456063A3 (en) 1-h-3-aryl-pyrrolidin-2,4-dion-derivatives
GB2251034B (en) Shrouded aerofoils
ZA913293B (en) 1,3-oxathiolane nucleoside analogues
DE68923951D1 (de) Hochgeschwindigkeits-Kombinierschalter mit Einzelfifo.
GB2228175B (en) Aseptically-packaged,aspartame-containing puddings
GB2265314B (en) Protective articles.
EG19674A (en) Antiviral tetrahydroimidazol (1,4) denzodiazepin -2-thiones
IL91430A0 (en) Fluorinated,carbonaceous articles
HU896535D0 (en) 14alpha, 17alpha-etano-estratriene-derivatives
EP0515668A4 (en) Oxo-tetrahydropyridazinyl-pyrazolo 4,3-b)-1,4-benzoxazines
GB8911158D0 (en) Antiviral pyridazinamines
HU913371D0 (en) Substituted tieno(3,2-b)pyran-5,7-diones
BA96097A (bs) Supstituirani 1,3-oksatiolani s antivirusnim svojstvima
CS275339B2 (en) N,o-dimethacryloylhydroxylamine
EP0421958A3 (en) High-speed hydrohull
ZA909616B (en) 14alpha,17alpha-ethano-16alpha-hydroxy-estratrienes
IE893635L (en) 14ó,17ó-ethanoestratrienes
GB9024371D0 (en) Putting,perceptor
IE900821L (en) 3-keto-16ó,17ó-dihydroxysteroids
HU896204D0 (en) Coloured, collapsible, plain toyfamily
IE880816L (en) 2',3'-dideoxynucleosides
IE881018L (en) 2ß,16ß-DIAMINO-ANDROSTANES
GB8919038D0 (en) Q,c,safegrip
HRP940041A2 (en) 1,3-oxathiolane nucleoside analogues